AROVI® and ROVI Biotech Ltd

The European Specialist in Heparins

November 2018
Disclaimer

This document has been prepared by Laboratorios Farmacéuticos Rovi, S.A. ("ROVI" or the "Company"), solely for its use during the attached presentation.

The information and each of the opinions and statements contained in this document have not been verified by independent experts and, therefore, no guarantee is provided of the impartiality, accuracy, completeness or precision of the information or opinions and statements contained in this presentation.

The Company and its advisors do not assume responsibility for any damage or losses that may arise from the use of this document or the information it contains.

This document does not constitute an offer or invitation to acquire or subscribe shares, in accordance with the Spanish Securities Market Law of 1988 and its implementing regulations. Moreover, this document does not constitute an offer to purchase, sell or exchange securities, a solicitation of any offer to purchase, sell or exchange securities, a solicitation of any kind of voting rights, or approval in the United States of America or any other jurisdiction.

Neither this document nor any part of it are of a contractual nature, and they cannot be used to form part or construe any agreement or any kind of undertaking.

This presentation may contain information and statements or declarations with future projections regarding ROVI. The future projections do not constitute historical facts and are generally identifiable by the use of terms such as “expects”, “anticipates”, “believes”, “intends”, “estimates” and similar expressions.

In this regard, although ROVI believes that the expectations contained in such statements are reasonable, the investors and holders of ROVI shares are advised that the information and future projections are subject to risks and uncertainties, a large part of which are difficult to foresee, and which are, in general, out of ROVI's control. These risks could cause the results and real development to differ substantially from those expressed, implicit or projected, in the information and future projections. Among these risks and uncertainties include those identified in the documents submitted by ROVI to the Spanish Securities Exchange Commission (Comisión Nacional del Mercado de Valores), which are available to the public.

It is recommended that investment decisions not be taken based on the future projections, which refer exclusively to the date on which they were publicised. All the future projections contained below and made by ROVI or any of its directors, managers, employees or representatives are expressly subject to the above warnings. The future projections included in this presentation are based on the information available on the date hereof. Except when legally required, ROVI does not assume any obligation to update its affirmations or review the future projections, even if new data is published or new facts arise.
Product Range
AROVI®: The same dosage, indications and method of administration as the reference medicine

<table>
<thead>
<tr>
<th>AROVI® Strentghs</th>
<th>Pack Sizes</th>
<th>Product License Number</th>
<th>PIP Code</th>
<th>EAN 13 CODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,000 IU (20 mg)/0.2 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0007</td>
<td>408-0867</td>
<td>8437009577-912</td>
</tr>
<tr>
<td>4,000 IU (40 mg)/0.4 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0008</td>
<td>408-0859</td>
<td>8437009577-929</td>
</tr>
<tr>
<td>6,000 IU (60 mg)/0.6 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0009</td>
<td>408-0875</td>
<td>8437009577-936</td>
</tr>
<tr>
<td>8,000 IU (80 mg)/0.8 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0010</td>
<td>408-0883</td>
<td>8437009577-943</td>
</tr>
<tr>
<td>10,000 IU (100 mg)/1 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0002</td>
<td>408-0891</td>
<td>8437009577-950</td>
</tr>
<tr>
<td>12,000 IU (120 mg)/0.8 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0006</td>
<td>406-1263</td>
<td>8437009577-899</td>
</tr>
<tr>
<td>15,000 IU (150 mg)/1 mL</td>
<td>10 Syringes</td>
<td>PL 15406/0003</td>
<td>406-1214</td>
<td>8437009577-905</td>
</tr>
</tbody>
</table>
Each PACK is color coded with a different color to avoid prescription and dispensing errors.
Each LABEL is color coded with a different color to avoid prescription and dispensing errors (example of PFS with activated device).
With easy-to-use safety device

Safety Device
AROVI® includes the safety device Preventis™ from Becton Dickinson

Preventis™ is an automatic needle shielding system. It has a cover or sleeve that extends over the needle following injection.

After the injection, further pressure on the plunger activates the spring causing the needle shield to automatically lock into place.
**Safety Device - AROVI®**

1. AROVI® 40mg *before* the injection
2. AROVI® 40mg *after* the injection with the needle shield locked into place.

Patients and Healthcare professionals safety is critical for us
AROVI® safety device is an "active" device versus other devices called "passive". The difference is that with an active device the patient controls the activation of the safety system.

1. After the injection, further pressure on the plunger rod activates the spring causing the needle shield to automatically lock into place.

2. The protective sleeve will automatically cover the needle producing an audible click.
Educational Materials
Educational Materials - AROVI®

1. A3 poster (for the wards)
2. A5 booklet (for patients)
3. Video

Available under request “free of cost”
14.8 x 21cm

Stapled Booklet

8 pages
3 – VIDEO – How to Inject - AROVI®

https://rovi.es/en/biosimilar-de-enoxaparina

AROVI® Administration VIDEO
Bioequivalence Study
Bioequivalence Study - AROVI®

AROVI® is biosimilar to the innovator Clexane®

Available here:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865560/pdf/ddd-12-575.pdf
ROVI Biotech Limited

Davis House, 4th Floor, Robert Street
CR0 1QQ Croydon
Tel.: +44 (0) 203 642 06 77

inforovibiotechUK@rovi.com
UK-medicalinformation@rovi.com

www.rovi.com/en